Wegovy vs Zepbound: Which GLP-1 Is Better?

Bold opening

Obesity is a chronic disease that demands evidence-based treatment. Two of the most talked-about medications today—Wegovy and Zepbound—have transformed weight management by leveraging gut hormone pathways. Both are injectable GLP-1 receptor agonists, but they differ in mechanism, efficacy, side effects, and cost. As an endocrinologist, I prescribe Wegovy and Zepbound daily, and the choice depends on patient history, tolerability, and insurance coverage. This article breaks down the science, safety, and practical considerations to help you understand which may be the better option for sustainable weight loss.

Wegovy vs Zepbound for Weight Loss

Clinical trials demonstrate that both Wegovy and Zepbound produce significant weight loss, but Zepbound has shown slightly greater efficacy in head-to-head studies. Wegovy, containing semaglutide, was approved by the FDA in 2021 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. In the STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks on Wegovy, compared to 2.4% with placebo.

Zepbound, approved in 2023, contains tirzepatide—a dual GLP-1 and GIP receptor agonist. In the SURMOUNT-1 trial, participants lost 20.9% of body weight over 72 weeks, outperforming Wegovy in direct comparisons. However, Wegovy has a longer track record, with real-world data supporting its safety and durability. While Zepbound may lead to faster initial weight loss, Wegovy remains a cornerstone for patients who tolerate it well or have insurance coverage limitations.

Side Effects Compared

Both Wegovy and Zepbound share common side effects due to their GLP-1 activity, including nausea, constipation, diarrhea, and abdominal discomfort. However, Zepbound’s additional GIP receptor agonism may contribute to a slightly different side effect profile.

In clinical trials, Wegovy’s most frequent side effects were gastrointestinal (GI), with nausea (44%), diarrhea (30%), and vomiting (24%) reported. These typically subside within weeks as the body adjusts. Zepbound, meanwhile, had higher rates of nausea (33%), diarrhea (23%), and constipation (21%) in SURMOUNT-1, though severe GI events were rare. Some patients on Zepbound also reported increased heart rate and injection-site reactions, which were less common with Wegovy.

A key difference is Zepbound’s potential to cause more pronounced fatigue or dizziness, possibly due to its dual mechanism. For patients with a history of pancreatitis or gallbladder disease, Wegovy may be preferred, as Zepbound’s long-term risks in these populations are still under study.

Cost: Wegovy vs Zepbound

Cost is a major barrier to accessing Wegovy and Zepbound, with both carrying list prices exceeding $1,000 per month. Wegovy’s price is approximately $1,349 for a 28-day supply, while Zepbound is priced slightly lower at $1,059. However, out-of-pocket costs vary widely based on insurance coverage, copays, and manufacturer savings programs.

Novo Nordisk offers a Wegovy savings card that can reduce costs to $25/month for eligible patients with commercial insurance. Eli Lilly’s Zepbound savings program similarly lowers out-of-pocket costs to $25/month for those with insurance. Without coverage, neither medication is affordable for most patients, though some turn to compounded semaglutide (for Wegovy) or clinical trials for Zepbound.

For Medicare beneficiaries, neither Wegovy nor Zepbound is covered for weight loss alone, though Wegovy is approved for reducing cardiovascular risk in patients with obesity and heart disease. Zepbound may gain similar approval in the future, but for now, cost remains a critical factor in choosing between the two.

How They Work Differently

Wegovy and Zepbound both target the GLP-1 receptor, but Zepbound adds a second mechanism that enhances its effects. Wegovy (semaglutide) is a GLP-1 receptor agonist, meaning it mimics the hormone GLP-1, which slows gastric emptying, reduces appetite, and increases satiety. This leads to lower calorie intake and sustained weight loss.

Zepbound (tirzepatide), however, is a dual GLP-1 and GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to enhance insulin secretion, improve glucose metabolism, and further suppress appetite. Studies suggest that GIP agonism may reduce nausea, a common side effect of GLP-1 drugs, though Zepbound’s clinical trials did not show a clear advantage in tolerability.

The dual mechanism likely explains Zepbound’s superior weight loss results. However, Wegovy’s single-target approach may be preferable for patients with type 2 diabetes, as semaglutide (under the brand name Ozempic) has well-established cardiovascular benefits. For now, Zepbound is the more potent option for weight loss, while Wegovy remains a trusted first-line therapy.

Which Is Better?

The “better” medication depends on individual patient factors. Zepbound is the clear winner in terms of efficacy, with nearly 6% more weight loss than Wegovy in clinical trials. For patients who have struggled with other weight loss methods, Zepbound may offer the best chance of significant, sustained results.

However, Wegovy has advantages in safety, accessibility, and long-term data. It has been studied for over a decade (including in its diabetes formulation, Ozempic), with proven benefits for cardiovascular risk reduction. Wegovy is also more likely to be covered by insurance for patients with obesity-related comorbidities, whereas Zepbound’s coverage is still expanding.

For patients who cannot tolerate GLP-1 side effects, Wegovy may be easier to titrate, as its once-weekly dosing starts at a lower dose (0.25 mg) before increasing. Zepbound’s starting dose (2.5 mg) is higher, which could lead to more initial nausea. Ultimately, Zepbound is better for maximal weight loss, while Wegovy is better for long-term safety and insurance coverage.

Switching Between Wegovy and Zepbound

Patients may consider switching from Wegovy to Zepbound (or vice versa) due to side effects, cost, or plateauing weight loss. For those on Wegovy who stop losing weight after 6–12 months, Zepbound may provide a new mechanism to restart progress. Conversely, patients who experience severe GI side effects on Zepbound may tolerate Wegovy better.

When switching, a washout period is not required, but dose adjustments are necessary. For example, a patient on Wegovy 2.4 mg could transition to Zepbound 10 mg (the mid-range dose) to minimize side effects. However, insurance may not cover the switch without prior authorization, and some patients experience temporary GI upset during the transition.

Before switching, patients should consult their provider to assess metabolic goals, side effect history, and insurance coverage. Some may benefit from combining lifestyle changes with the new medication to optimize results.

Insurance Coverage Compared

Insurance coverage is a major deciding factor between Wegovy and Zepbound. Wegovy is more widely covered, particularly for patients with obesity-related conditions like type 2 diabetes, hypertension, or sleep apnea. Medicare does not cover Wegovy for weight loss alone but may cover it for cardiovascular risk reduction in patients with heart disease.

Zepbound’s coverage is growing but less consistent. Some commercial insurers cover it for obesity, while others require prior authorization or limit it to patients with diabetes. Medicaid coverage varies by state, and Zepbound is not yet approved for cardiovascular risk reduction, which may limit its accessibility.

Patients should check with their insurer before starting either medication. Manufacturer savings programs can help, but long-term affordability remains a challenge. For those without coverage, clinical trials or compounded semaglutide (for Wegovy) may be alternatives.

Frequently Asked Questions

Is Wegovy or Zepbound better?

Zepbound is more effective for weight loss, with ~20% body weight reduction vs. ~15% for Wegovy. However, Wegovy has a longer safety record and may be better tolerated. The best choice depends on individual goals, side effects, and insurance coverage.

Can you switch from Wegovy to Zepbound?

Yes, but dose adjustments are needed to avoid side effects. Some patients switch if they plateau on Wegovy or experience intolerable side effects. Insurance may require prior authorization for the change.

Which has fewer side effects?

Both cause GI side effects, but Wegovy may be slightly better tolerated due to its lower starting dose. Zepbound’s dual mechanism can cause more fatigue or dizziness, though some patients report less nausea over time.

Disclaimer from Dr. Nina Patel: The information in this article is for educational purposes only and does not replace medical advice. Wegovy and Zepbound are prescription medications with risks and benefits that should be discussed with a healthcare provider. Individual results vary, and lifestyle changes (diet, exercise, behavior therapy) are essential for long-term success. Always consult your doctor before starting or switching medications.